BIOLINGUS

Our company

BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins for chronic diseases and immune-therapies. It is a cutting-edge and mature solution for oral formulations, not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies, vaccines, immunotherapies etc.

NEWS

- BioLingus in list of "Top 20 Most Influential Companies" from CEO Insight
- Two prestigious awards from CEO Monthly Magazine 2017
- For the second time, BioLingus has been awarded the "GAMECHANGER AWARD" from the ACQ 2017 Global Awards Program.
- BioLingus wins Best Delivery System Award from the Global Health & Packaging magazine

NEWS



OCT 2017

BioLingus in list of "Top 20 Most Influential Companies" from CEO Insight.

[Read More]

JUL 2017

Best European CEO Biotech – Europe
Most Innovative Biotech company – Europe
[Read More]



Technology


CSSR

The Cytokine Stabilisation and Slow Release (CSSR) technology is the "mother" of the BioLingus technologies.


SEED

Through advanced "bio-engineering", the BioLingus SEED Technology is mimicking what is happening in nature in a plant SEED.


OPUS

The OPUS (Oral Peptide Utility System) is our technology application to orally (sublingually) or via the mucosum administer peptides which have no immunomodulatory mode of action.

SLIT

Due to the fact that BioLingus drug administration is sublingual, and the use of a specific carrier molecule in the BioLingus formulation, the BioLingus technology is particularly effective for sublingual immuno therapy.

Corporate Partnerships


Corporate Partnerships

To further exploit the potential of the BioLingus Technology, we are interested in exploring partnerships with other pharmaceutical companies. Aside from pharmaceutical companies, we are also interested in working with animal health companies" (with adjusted formulations) and food companies working on innovative food supplements.

Together we unlock the potential of the BioLingus Technology, and thus transform current standard practices in the administration of peptides and proteins.


Contacts



Main Office
BioLingus AG

Grossmatt 6
CH-6052 Hergiswil NW
Switzerland
Email
info@biolingus.ch